Education
About Us
Working with TipRanks
Follow Us
Bvf Partners LP Il Insider Profile
396 Followers
Bvf Partners LP Il, See Explanation of Responses at ChemoCentryx, holds 353.41K shares in Kymera Therapeutics (Ticker: KYMR), holds 62.38K shares in Crescent Biopharma (Ticker: CBIO), holds 1.27M shares in Xoma (Ticker: XOMA). Most recently, Bvf Partners LP Il Bought ― shares of Kymera Therapeutics on Jul 01, 2025 for an estimated value of 13.96M.
Bvf Partners LP Il ChemoCentryx (CCXI)See Explanation of Responses
ChemoCentryx (CCXI)
See Explanation of Responses
Ranked #31 out of 102,674 Corporate Insiders
Profitable Transactions
93 out of 144 Profitable Transactions
Average Return
+50.80%
Average return per transaction
Time Frame
Compare to
Insider Holdings
A breakdown of Bvf Partners LP Il's holdings
Insider Roles
Roles that Bvf Partners LP Il holds in companies
Most Profitable Insider Trade
Stock:
Five Prime Therapeutics
(FPRX)
(FPRX)
Rating:Informative Buy
Date:Nov 26, 2019 - Nov 26, 2020
Return:+467.90%
The most profitable trade made by Bvf Partners LP Il
Bvf Partners LP Il's Trading History
ChemoCentryx
Nov 05, 2015
―
Uninformative Sell
―
$177.51M
CTI BioPharma
Jun 28, 2023
―
Uninformative Sell
80.59M
$0.00
Xenon
Mar 29, 2018
Ten Percent Owner
Uninformative Sell
―
$1.82M
Infinity Pharmaceuticals
Feb 16, 2021
See Explanation of Responses
Informative Sell
12.11M
―
Xoma
May 20, 2025
Ten Percent Owner
Informative Sell
10.64M
$31.54M
Crescent Biopharma
Jun 17, 2025
Ten Percent Owner
Uninformative Buy
―
$774.80K
Concert Pharma
Jun 12, 2019
―
Informative Sell
4.13M
$1.42M
Syndax Pharmaceuticals
Jun 20, 2018
Ten Percent Owner
Uninformative Sell
―
$843.58K
Immune Design
Dec 04, 2018
―
Informative Sell
1.65M
$2.17M
Palvella Therapeutics
Dec 17, 2024
See Explanation of Responses
Uninformative Buy
―
$1.43M
Five Prime Therapeutics
Nov 13, 2020
―
Informative Sell
149.20M
$3.09M
Calithera Bio
May 26, 2020
―
Informative Sell
13.70M
$12.01K
Cytokinetics
Feb 18, 2020
See Explanaton of Responses
Informative Sell
16.92M
$265.96M
Merus
Oct 08, 2021
Ten Percent Owner
Informative Sell
31.22M
$15.42M
IDEAYA Biosciences
Feb 04, 2021
See Explanation of Responses
Informative Sell
835.36K
$5.68M
Principia Biopharma
―
―
―
―
Kymera Therapeutics
Jul 01, 2025
Director, See Remarks and Footnotes
Informative Buy
13.96M
$15.46M
Olema Pharmaceuticals
Jan 14, 2025
Director, See Explanation of Responses
Uninformative Sell
―
$26.25M
Eledon Pharmaceuticals
May 13, 2024
Ten Percent Owner
Uninformative Buy
―
$19.58M
CytomX Therapeutics
―
See Explanation of Responses
―
$11.98M
Rain Oncology
Jan 29, 2024
―
Uninformative Sell
―
$0.00
Repare Therapeutics
Nov 17, 2023
Ten Percent Owner
Informative Buy
6.24M
$828.90K
Cullinan Management
Jan 19, 2023
Ten Percent Owner
Uninformative Sell
―
$498.53K
Third Harmonic Bio, Inc.
Oct 31, 2024
See Explanation of Responses
Informative Sell
14.30M
$950.60K
Structure Therapeutics, Inc. Sponsored ADR
May 12, 2023
Ten Percent Owner
Uninformative Sell
―
$92.10M
MoonLake Immunotherapeutics
Oct 08, 2024
Director, Ten Percent Owner
Informative Sell
100.00M
$993.25M
POINT Biopharma Global
Dec 20, 2023
―
Informative Sell
213.66M
$0.00
4D Molecular Therapeutics
Nov 13, 2024
See Explanation of Responses
Uninformative Sell
―
$395.60K
Allakos
May 19, 2025
―
Uninformative Sell
―
$0.00
Gyre Therapeutics
Nov 19, 2012
See Explanation of Responses
Informative Buy
5.24M
$16.96M
Cascadian Therapeutics
Dec 22, 2015
―
Informative Buy
―
$207.39M
Dynavax
Sep 11, 2009
Ten Percent Owner
Informative Sell
3.35M
$187.93M
Neurocrine
Oct 14, 2011
See Explanation of Responses
Informative Buy
175.53K
$1.16B
Repligen
Jul 08, 2009
Indirect Beneficial Owner, Ten Percent Owner
Informative Sell
5.50K
$1.29B
Epirus Biopharma
Dec 24, 2009
―
Informative Sell
2.54M
$13.66M
Array Biopharma
Jul 10, 2014
―
Uninformative Sell
2.25M
$596.76M
Amag Pharmaceuticals
―
―
―
$14.15M
Arqule
Jun 01, 2018
―
Informative Sell
5.18M
$15.43M
Rigel
Nov 20, 2013
Ten Percent Owner
Informative Sell
1.28M
$160.24M
Tobira Therapeutics
Mar 25, 2014
―
Uninformative Sell
―
$47.19M
Curis
Apr 29, 2009
Indirect Beneficial Owner, Ten Percent Owner
Informative Sell
3.42M
$9.88M
Repros
―
―
―
$1.12M
Ligand Pharma
Mar 26, 2014
See Explanation of Responses
Informative Sell
5.48M
$17.13M
Palatin Technologies
Mar 03, 2014
Ten Percent Owner
Informative Sell
320.27K
$523.85K
Astex Pharmaceuticals
―
―
―
―
Medicinova
―
Ten Percent Owner
―
$0.00
NPS Pharma
―
―
―
―
List of latest transactions for each holding click on a transaction to see Bvf Partners LP Il's performance on stock
You May Also Like
Bvf Partners LP Il insider profile FAQ
What is the percentage of profitable transactions made by Bvf Partners LP Il?
The percentage of profitable transactions made by Bvf Partners LP Il is 65%.
What is the average return per transaction made by Bvf Partners LP Il?
The average return per transaction made by Bvf Partners LP Il is 50.80%.
What stocks does Bvf Partners LP Il hold?
Bvf Partners LP Il holds: CCXI, CTIC, XENE, INFIQ, XOMA, CBIO, CNCE, SNDX, IMDZ, PVLA, FPRX, CALA, CYTK, MRUS, IDYA, PRNB, KYMR, OLMA, ELDN, CTMX, RAIN, RPTX, CGEM, THRD, GPCR, MLTX, PNT, FDMT, ALLK, GYRE, CASC, DVAX, NBIX, RGEN, EPRSQ, ~ARRY, AMAG, ARQL, RIGL, TBRA, CRIS, ~RPRX, LGND, PTNT, ~ASTX, MNOV, NPSP stocks.
What was Bvf Partners LP Il’s latest transaction?
Bvf Partners LP Il latest transaction was an Informative Buy of $13.96M.
What was Bvf Partners LP Il's most profitable transaction?
Bvf Partners LP Il’s most profitable transaction was an Informative Buy of FPRX stock on November 26, 2019. The return on the trade was 467.90%.
What is Bvf Partners LP Il's role in ChemoCentryx?
Bvf Partners LP Il's role in ChemoCentryx is See Explanation of Responses.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.